News | Left Atrial Appendage (LAA) Occluders | December 29, 2015

American College of Cardiology Launches Left Atrial Appendage Occlusion Registry

Registry will track use, results of new stroke prevention technology in atrial fibrillation patients

watchman LAA occluder, LAAO registry

Implantation of the Boston Scientific Watchman LAA occluder.

December 29, 2015 — The American College of Cardiology (ACC) launched the new Left Atrial Appendage Occlusion (LAAO) Registry Dec. 16. It will to capture data on a new class of medical devices used in left atrial appendage (LAA) occlusion procedures.

The LAA is a muscular pouch connected to the left atrium of the heart where blood can gather and lead to blood clots that can cause stroke in patients with atrial fibrillation. Left atrial appendage occlusion or closure procedures and devices can reduce stroke risk as an alternative to anticoagulation with medications among patients with non-valvular atrial fibrillation.

The LAAO Registry will help assess real-world procedural indications and outcomes as well as short- and long-term safety of procedures and devices for closing the left atrial appendage.  Paul D. Varosy, M.D., FACC, FAHA, FHRS, who is director of cardiac EP at VA Eastern Colorado Health Care System, is the lead physician for the data set development work group for the LAAO Registry.

The registry will serve not only as the formal FDA-mandated post-approval study for the Boston Scientific Watchman device, but it is also expected to serve as a long-term clinical registry for all patients undergoing occlusion of the left atrial appendage, regardless of the device used.

“It is exciting that we are launching this registry at the beginning of implementation of this transformative therapy,” Varosy said. “Clinicians, hospitals, payers, and especially patients will benefit from a clear understanding of how these devices are being used in real-world practice. A registry like this can provide important tools in ensuring that the quality of care is as high as it can be for patients receiving these devices.”

The new clinical registry program joins eight other programs that comprise the National Cardiovascular Data Registry, the ACC's suite of cardiovascular data registries that help hospitals and clinical practices measure and improve the quality of care they provide. Additionally, an atrial fibrillation ablation registry, officially the AFib Ablation Registry, is expected to launch in 2016.

For more information: acc.org

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init